IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

Published:2019-10 Issue: Volume:30 Page:v915
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Spigel D.,de Marinis F.,Giaccone G.,Reinmuth N.,Vergnenegre A.,Barrios C.H.,Morise M.,Felip E.,Andric Z.G.,Geater S.,Özgüroğlu M.,Mocci S.,McCleland M.,Enquist I.,Komatsubara K.M.,Deng Y.,Kuriki H.,Wen X.,Jassem J.,Herbst R.S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz293/30082716/mdz293.pdf

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of a proteomic signature for predicting immunotherapy response in patients with metastatic non-small cell lung cancer;Molecular & Cellular Proteomics;2024-08

2. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma;PLOS ONE;2024-07-22

3. Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study;Cancer Immunology, Immunotherapy;2024-05-07

4. Immune checkpoint inhibitor for different age patients with NSCLC in efficacy: A systematic review and meta-analysis;Asian Journal of Surgery;2024-04

5. PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer;Medicina;2024-03-14